Herein, we report the structure-activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) positive allosteric modulators (PAMs). On the basis of its robust in vitro potency and in vivo efficacy in multiple preclinical models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, 17a (VU0409551/JNJ-46778212) was selected as a candidate for further development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492464 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.5b00181 | DOI Listing |
Publication Analysis
Top Keywords
mglu5 positive
8
positive allosteric
8
discovery vu0409551/jnj-46778212
4
vu0409551/jnj-46778212 mglu5
4
allosteric modulator
4
modulator clinical
4
clinical candidate
4
candidate targeting
4
targeting schizophrenia
4
schizophrenia report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!